Real World Evidence Study in Subjects With Wilson's Disease

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Wilson Disease
Interventions
DIAGNOSTIC_TEST

NCC-Sp Assay

Orphalan has developed a new NCC speciation assay (NCC-Sp) using liquid chromatography inductively coupled plasma mass spectroscopy (LC-ICP-MS) to measure serum copper and ceruloplasmin bound copper from which non ceruloplasmin bound copper (NCC) is estimated.

Trial Locations (9)

10032

New York Presbyterian Hospital-Columbia University Medical Centre, New York

21287

John Hopkins Hospital, Baltimore

32803

Advent Health Orlando, Orlando

33136

University of Miami, Miami

37212

Vanderbilt University Medical Centre, Nashville

48109

University of Michigan, Ann Arbor

60611

Northwestern University Chicago (Hepatologist), Chicago

95817

UC Davis Midtown Ambulatory Care Centre, Sacramento

06520

Yale University School of Medicine, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Orphalan

INDUSTRY

NCT05783687 - Real World Evidence Study in Subjects With Wilson's Disease | Biotech Hunter | Biotech Hunter